Expertise in
1
conditions

Alfredo Pece

Milan, IT 
Expertise in
1
conditions
Milan, IT 

Overview

Alfredo Pece practices practicing medicine in Milan, Italy.

Mr. Pece is highly rated in 1 condition, according to our data. His clinical expertise encompasses Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Cavernous Sinus Thrombosis, Nearsightedness, and Vitrectomy.

He is actively involved in clinical research, co-authoring 51 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Milan, Italy
Other Locations
Via Pandina, 1, Vizzolo Predabissi, 20077, Italy
Melegnano, Italy
Palermo, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

An International, Multicenter, Randomized, Blinded-assessor, Parallel-group Clinical Study Comparing Eye Drops of Combined LEvofloxAcin + DExamethasone foR 7 Days Followed by Dexamethasone Alone for an Additional 7 Days vs. Tobramycin + Dexamethasone for 14 Days for the Prevention and Treatment of Inflammation and Prevention of Infection Associated With Cataract Surgery in Adults - LEADER 7
An International, Multicenter, Randomized, Blinded-assessor, Parallel-group Clinical Study Comparing Eye Drops of Combined LEvofloxAcin + DExamethasone foR 7 Days Followed by Dexamethasone Alone for an Additional 7 Days vs. Tobramycin + Dexamethasone for 14 Days for the Prevention and Treatment of Inflammation and Prevention of Infection Associated With Cataract Surgery in Adults - LEADER 7
Enrollment Status: Completed
Publish Date: August 18, 2020
Intervention Type: Drug
Study Phase: Phase 3

51 Total Publications

Reducing the Carbon Footprint of Neovascular Age-Related Macular Degeneration Therapy: Environmental Impact of Transitioning to Aflibercept 8 mg.
Reducing the Carbon Footprint of Neovascular Age-Related Macular Degeneration Therapy: Environmental Impact of Transitioning to Aflibercept 8 mg.
Journal: Journal of ophthalmology
Published: May 29, 2025

Frequently Asked Questions about Alfredo Pece

Is Alfredo Pece a top-rated expert for Late-Onset Retinal Degeneration?

MediFind is an objective health platform that identifies experts based on real-world data. Alfredo Pece is classified as an Advanced expert for Late-Onset Retinal Degeneration, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Alfredo Pece participate in research or clinical trials?

Yes. Alfredo Pece has published 51 articles and abstracts on conditions like Late-Onset Retinal Degeneration. You can view a list of Alfredo Pece's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pece's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile